The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections
| author | |
| created | [InstanceEdit:9733013] Stephan, Ralf, 2021-06-01 |
| dbId | 9732794 |
| displayName | The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections |
| journal | J Med Virol |
| pages | 2087-2095 |
| pubMedIdentifier | 32374457 |
| schemaClass | LiteratureReference |
| title | The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections |
| url | http://www.ncbi.nlm.nih.gov/pubmed/32374457 |
| volume | 92 |
| year | 2020 |
Referrals
| (literatureReference) | |
| (author) |
© 2026 Reactome
